Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01259908
Other study ID # 2010/1953-4
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2010
Est. completion date May 2023

Study information

Verified date June 2023
Source Oslo University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients with aorto-iliac occlusive disease (TASC, type D) operated with a totally laparoscopic aortobifemoral bypass operation and open aortobifemoral bypass operation will be followed up and the results will be compared between the two procedures on the basis of the primary endpoint, a composite endpoint defined as a combined incidence of systemic morbidity, graft thrombosis and all-cause mortality.


Description:

Patients with aorto-iliac occlusive disease (TASC, type D) operated with a totally laparoscopic aortobifemoral bypass operation and open aortobifemoral bypass operation will be followed up and the results will be compared between the two procedures on the basis of the primary endpoint, a composite endpoint defined as a combined incidence of systemic morbidity, graft thrombosis and all-cause mortality. Secondary endpoints like length of hospital stay, operation time, bleeding time shall also be considered. Besides short form- 36 (SF-36) shall be used for the evaluation of patients health related quality of life, preoperatively,1,3,and 6 months and 1 year post-operatively. Early, midterm and long time results shall be followed.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date May 2023
Est. primary completion date May 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility All patients with a TASC D lesion in the aorto-iliac segment not amenable to or previously unsuccessfully treated by endovascular approach. Exclusion Criteria: - Unsuitable for surgery due to general health status

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Laparoscopic vs open Ygraft
Patients with aorto-iliac occlusive disease TASC type D operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared.

Locations

Country Name City State
Norway Oslo University Hospital Oslo

Sponsors (3)

Lead Sponsor Collaborator
Oslo University Hospital Sorlandet Hospital HF, Sykehuset Ostfold

Country where clinical trial is conducted

Norway, 

References & Publications (2)

Kazmi SS, Jorgensen JJ, Sundhagen JO, Krog AH, Florenes TL, Kolleros D, Abdelnoor M. A comparative cohort study of totally laparoscopic and open aortobifemoral bypass for the treatment of advanced atherosclerosis. Vasc Health Risk Manag. 2015 Sep 18;11:541-7. doi: 10.2147/VHRM.S92671. eCollection 2015. — View Citation

Kazmi SS, Krog AH, Berge ST, Sundhagen JO, Sahba M, Falk RS. Patient-perceived health-related quality of life before and after laparoscopic aortobifemoral bypass. Vasc Health Risk Manag. 2017 May 12;13:169-176. doi: 10.2147/VHRM.S134669. eCollection 2017. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Composite endpoint (All-cause mortality, graft occlusion and systemic morbidity) Composite endpoint defined as all-cause mortality, systemic morbidity and graft thrombosis.
In this prospective comparative cohort study 50 consecutive patients with type D atherosclerotic lesions in the aortoiliac segment were treated with laparoscopic aortobifemoral bypass operation. The group was compared with 30 patients operated with open aortobifemoral bypass operations for the same disease and period of time. The groups were compared on the basis of composite endpoint All-cause mortality, graft occlusion and systemic morbidity). Stratification analysis was performed by using Mantel-Haenszel method with the patient time model. Cox multivariate regression method was used to adjust for confounding effect after considering the proportional hazard assumption. Cox proportional cause-specific hazard regression model was used for competing risk endpoints. Comparison of survival curves was done with the help of log- rank test.
2005-2015
Secondary Operative time, operative bleeding, length of hospital stay, quality of life Linear regression model was used to control for the confounding effect of the secondary continuous outcomes. 2005-2015